BioPharmSignal logoBioPharmSignal

Biotech News

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Corvus Pharmaceuticals (CRVS)Corvus PharmaceuticalsEarnings

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on

Related news

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

IMCRImmunocore Holdings plc2026-07-30 11:00 EST

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

View all latest news

Corvus Pharmaceuticals

ITK Inhibition Corvus Pharmaceuticals develops therapies based on inhibition of interleukin-2-inducible T-cell kinase, or ITK. The approach is intended to rebalance immune-cell activity in inflammatory diseases and cancer. Soquelitinib Soquelitinib is an oral, selective ITK inhibitor. Its lead immunology program is a Phase 2 study in...

Recent company news

CRVSCorvus Pharmaceuticals2026-08-06 20:01 EST

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

CRVSCorvus Pharmaceuticals2026-07-30 20:01 EST

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

CRVSCorvus Pharmaceuticals2026-06-09 11:30 EST

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

CRVSCorvus Pharmaceuticals2026-05-20 20:01 EST

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

CRVSCorvus Pharmaceuticals2026-05-14 11:00 EST

Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

Stock data

Close
13.86 USD
Market cap
983.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States